Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy

The overexpression of myeloid cell leukemia-1 (MCL-1) has been identified in numerous hematologic malignancies and solid tumors. Currently, there are no selective MCL-1 inhibitors. Here, we present a case of left kidney undifferentiated spindle cell sarcoma with MCL-1 amplification. The tumor showed...

書誌詳細
出版年:	Journal of Cancer Research and Practice
主要な著者:	Cheng-Yu Tang, Chueh-Chuan Yen
フォーマット:	論文
言語:	英語
出版事項:	Wolters Kluwer Medknow Publications 2023-10-01
主題:	bortezomib myeloid cell leukemia-1 amplification sarcoma venetoclax
オンライン･アクセス:	https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00026

類似資料

Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report
著者:: Kavya Sudireddy, 等
出版事項: (2025-01-01)

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
著者:: Xinyi Jian, 等
出版事項: (2024-06-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
著者:: Dong Liang, 等
出版事項: (2024-09-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
著者:: I. V. Cherkashina, 等
出版事項: (2025-03-01)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia
著者:: XIANG Caixia, HUANG Bintao, HAO Jian
出版事項: (2023-05-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
著者:: Mariarita Sciumè, 等
出版事項: (2023-03-01)

Real-world experience of venetoclax target dosing with concomitant posaconazole in adult patients with acute myeloid leukemia
著者:: Tracelyn Freeman, 等
出版事項: (2025-09-01)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
著者:: Xiang Zhang, 等
出版事項: (2021-05-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
著者:: Xubo Gong, 等
出版事項: (2024-02-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
著者:: Xubo Gong, 等
出版事項: (2023-06-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
著者:: Zhangjie Chen, 等
出版事項: (2023-03-01)

Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
著者:: Yuina Akagi, 等
出版事項: (2023-08-01)

Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
著者:: Qingyang Liu, 等
出版事項: (2025-03-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
著者:: Matteo Piccini, 等
出版事項: (2023-05-01)

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V<sup>2</sup>) Therapy
著者:: Kyle C. Roche, 等
出版事項: (2022-06-01)

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience
著者:: İbrahim Ethem Pınar, 等
出版事項: (2021-03-01)

Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
著者:: Xushu Zhong, 等
出版事項: (2024-12-01)

Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies
著者:: Katherine Parks, 等
出版事項: (2024-06-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
著者:: Xi Xu, 等
出版事項: (2023-10-01)

Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling
著者:: Lin Chen, 等
出版事項: (2023-09-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
著者:: Kendall Diebold, 等
出版事項: (2025-06-01)

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis
著者:: Omar S. Al-Odat, 等
出版事項: (2024-10-01)

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study
著者:: Jie-Fei Bai, 等
出版事項: (2025-06-01)

Myeloid Sarcoma Presenting as Obstructive Jaundice
著者:: Matthew Patterson, 等
出版事項: (2021-08-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
著者:: Musa Fares Alzahrani
出版事項: (2024-12-01)

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
著者:: Wenxiu Shu, 等
出版事項: (2025-05-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
著者:: Jenna L. Carter, 等
出版事項: (2025-01-01)

Multi‐Omic Analysis Reveals the Impact of Bortezomib in Hyperleukocytic Acute Myeloid Leukemia
著者:: Jinxian Wu, 等
出版事項: (2024-11-01)

The efficacy of varying doses of venetoclax combined with azacitidine for newly diagnosed adult acute myeloid leukemia in real-world settings: a single-center retrospective analysis
著者:: Yanjie Mao, 等
出版事項: (2025-12-01)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
著者:: Alicia Roldán Pérez, 等
出版事項: (2022-07-01)

Identification of a venetoclax-resistance prognostic signature base on 6-senescence genes and its clinical significance for acute myeloid leukemia
著者:: Peng Ke, 等
出版事項: (2023-11-01)

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
著者:: Jiaying Cheng, 等
出版事項: (2025-09-01)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
著者:: Xiaohui Suo, 等
出版事項: (2023-05-01)

Myeloid Sarcomas: A Clinicopathologic Study of 20 Cases
著者:: Gülşah Kaygusuz, 等
出版事項: (2015-02-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
著者:: Daniela Taurino, 等
出版事項: (2021-08-01)

A common ground: an in silico assessment of the sources of intrinsic ex vivo resistance to venetoclax in acute myeloid leukemia
著者:: Brunno Gilberto Santos de Macedo, 等
出版事項: (2025-04-01)

Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
著者:: Jie Jin, 等
出版事項: (2024-03-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
著者:: Xuezhu Xu, 等
出版事項: (2023-12-01)

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report
著者:: Si‐Man Huang, 等
出版事項: (2023-01-01)

Gastric Myeloid Sarcoma
著者:: Pedro Marcos, 等
出版事項: (2019-12-01)